Comparison of Different Covid-19 Vaccines Globally: An Overview

Asif Bilal
{"title":"Comparison of Different Covid-19 Vaccines Globally: An Overview","authors":"Asif Bilal","doi":"10.19080/jgwh.2021.21.556071","DOIUrl":null,"url":null,"abstract":"It was 2012 when the first case of corona virus noticed by the Saudi Authorities which spread through the Asian countries, also flown to European countries. In 1960 revealed the presence of the corona virus when it was declared as the reason of common cold in human beings. On January 30, 2020, the WHO declared the COVID-19 outbreak a global health emergency. On March 11, 2020, the WHO declared COVID-19 a global pandemic. There are three brands of vaccines available that are Pfizer, Moderna and Johnson & Johnson (Janssen). A mild difference may present as post vaccination effects. The Pfizer–BioNTech COVID-19 vaccine is based as mRNA and marketed as Comirnaty. Pfizer reported a 91 percent efficacy rate after six months, while Moderna reported a 94 percent efficacy rate. Moderna, we are pioneering a class of medicines based on messenger RNA (mRNA). The Janssen COVID-19 Vaccine may not protect everyone. Mostly 2 doses of the vaccine are required to protect and these are intramuscular injections. Its quantity would be changed in different age groups. Some common side effects include fatigue, headache, and pain in joints, fever, chills, and muscle pain. However everyone should vaccinated for protection of corona virus disease.","PeriodicalId":376391,"journal":{"name":"Journal of Gynecology and Womens Health","volume":"159 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gynecology and Womens Health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.19080/jgwh.2021.21.556071","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

It was 2012 when the first case of corona virus noticed by the Saudi Authorities which spread through the Asian countries, also flown to European countries. In 1960 revealed the presence of the corona virus when it was declared as the reason of common cold in human beings. On January 30, 2020, the WHO declared the COVID-19 outbreak a global health emergency. On March 11, 2020, the WHO declared COVID-19 a global pandemic. There are three brands of vaccines available that are Pfizer, Moderna and Johnson & Johnson (Janssen). A mild difference may present as post vaccination effects. The Pfizer–BioNTech COVID-19 vaccine is based as mRNA and marketed as Comirnaty. Pfizer reported a 91 percent efficacy rate after six months, while Moderna reported a 94 percent efficacy rate. Moderna, we are pioneering a class of medicines based on messenger RNA (mRNA). The Janssen COVID-19 Vaccine may not protect everyone. Mostly 2 doses of the vaccine are required to protect and these are intramuscular injections. Its quantity would be changed in different age groups. Some common side effects include fatigue, headache, and pain in joints, fever, chills, and muscle pain. However everyone should vaccinated for protection of corona virus disease.
全球不同Covid-19疫苗的比较综述
2012年,沙特当局发现了首例冠状病毒病例,这种病毒在亚洲国家传播,也传播到了欧洲国家。1960年发现了冠状病毒的存在,当时它被宣布为人类普通感冒的原因。2020年1月30日,世界卫生组织宣布新冠肺炎疫情为全球卫生紧急情况。2020年3月11日,世界卫生组织宣布COVID-19为全球大流行。有三个品牌的疫苗可供选择,分别是辉瑞、Moderna和强生(杨森)。轻微的差异可能表现为接种后的影响。辉瑞- biontech的COVID-19疫苗以mRNA为基础,以Comirnaty的名称上市。辉瑞报告6个月后的有效率为91%,而Moderna报告的有效率为94%。现代,我们正在开拓一类基于信使RNA (mRNA)的药物。杨森COVID-19疫苗可能无法保护所有人。通常需要2剂疫苗来保护,这些是肌肉注射。它的数量在不同的年龄组会有所不同。一些常见的副作用包括疲劳、头痛、关节痛、发烧、发冷和肌肉痛。然而,每个人都应该接种疫苗以预防冠状病毒病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信